During the short history of Oncotarget and Oncoscience, a number of our members have also joined the National Academy of Sciences USA, and have won Lasker, Nobel and other prestigious awards.

Oncotarget is indexed/archived on PubMed and PMC.

All volumes (1-10) of Oncotarget are available on PubMed »
Volume 11 (2020) issues (1-41) are now on PubMed »

As stated by MEDLINE reviewers on 6/22/2017,
"This journal continues to play a major role in the publication of important basic science research papers. Editorial practices are consistently high. Ethical guidelines are consistently followed. This is an important research journal for the field."

Cision PR Newswire.

Impact factor (IF) Web of Science (Clarivate Analytics)

Year IF Total Cites
2016 5.168 30241
2015 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493

Web of Science Update »

Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine and Oncology (subject area).

Oncotarget ranks number 1 for Total Cites (2017-2019) among all journals in Oncology.

News: (June 2020), Scopus has released its latest 2019 ratings. Oncotarget is in Q1 (highest rank). Furthermore, Oncotarget ranks No. 1 for total cites (2019) in Oncology.

Andrew V. Schally, a member of the Editorial Board of Oncotarget, a Nobel Prize winner in Physiology or Medicine: “Oncotarget is an outstanding and most important journal in the field of oncology and cancer research. Oncotarget is performing an extremely useful function for those of us working not only in cancer research, but also on other important topics in the field of medicine. Oncotarget deserves a strong support from investigators working in the area of oncology as well as from NIH.”

Andrew V. Schally has published 12 papers in Oncotarget

Copyright © 2020 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC